Last reviewed · How we verify
Thrombolytic
Thrombolytic is a Small molecule drug developed by Faculty Hospital Kralovske Vinohrady. It is currently FDA-approved. Also known as: intravenous thrombolysis.
Thrombolytic therapy is used to break down blood clots formed in blood vessels, and it is indicated for conditions such as acute ischemic stroke, stroke, and severe venous thromboembolism. The therapy involves the use of medication to dissolve blood clots, and it is often used in conjunction with telemedicine-supported management in basic-level hospitals.
At a glance
| Generic name | Thrombolytic |
|---|---|
| Also known as | intravenous thrombolysis |
| Sponsor | Faculty Hospital Kralovske Vinohrady |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure (NA)
- Normal Saline Infusion After Intravenous Thrombolysis in Stroke (PHASE3)
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
- Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
- Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO) (PHASE3)
- Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
- Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thrombolytic CI brief — competitive landscape report
- Thrombolytic updates RSS · CI watch RSS
- Faculty Hospital Kralovske Vinohrady portfolio CI
Frequently asked questions about Thrombolytic
What is Thrombolytic?
Who makes Thrombolytic?
Is Thrombolytic also known as anything else?
What development phase is Thrombolytic in?
Related
- Manufacturer: Faculty Hospital Kralovske Vinohrady — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Also known as: intravenous thrombolysis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing